Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation

NCT06911944 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Down Syndrome (DS)
Down Syndrome (Trisomy 21)
Alzheimer Disease
Amyloid Beta Protein

Interventions

DRUG: Donanemab
DRUG: Placebo

Sponsor

Michael Rafii, MD, PhD

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]